RSV vaccine from GSK shows potential to protect adults 50 to 59
Publishing timestamp: 2023-10-25 11:07:38
Summary
GlaxoSmithKline's vaccine, Arexvy, has shown potential to protect adults ages 50 to 59 from respiratory syncytial virus (RSV) in a late-stage clinical trial. The vaccine is already approved for adults ages 60 and older and the company plans to submit data for potential label expansion in 2024. Pfizer is another company with an approved RSV vaccine. U.S. health officials are relying on these vaccines to combat this year's RSV season, which was severe last year. RSV causes hospitalizations and deaths among older Americans each year.
Sentiment: POSITIVE
Keywords: business news, business, gsk plc, breaking news, health care industry, pharmaceuticals, immunizations, biotechnology, social issues, pfizer inc, biotech and pharmaceuticals, united states, respiratory syncytial virus,
Source: https://www.cnbc.com/2023/10/25/gsk-rsv-vaccine-shows-potential-to-protect-adults-50-to-59.html